FDA has approved a new tablet formulation of Brukinsa (zanubrutinib) for all five approved indications. Brukinsa remains the leader in new chronic lymphocytic leukemia patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
